Viracta Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 40
- Market Cap
- $8.7M
- Website
- http://www.viracta.com
- Introduction
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.
Clinical Trials
12
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers
- Conditions
- Advanced Cancer
- Interventions
- Drug: Single-agent Nanatinostat (free base) tabletsDrug: [14C]-Nanatinostat
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Viracta Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06302140
- Locations
- 🇪🇸
START Madrid - CIOCC - Hospital Universitario HM Sanchinarro, Madrid, Spain
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
- Conditions
- Nasopharyngeal CarcinomaEBV-Related Gastric CarcinomaEBV-Related LeiomyosarcomaEBV Related CarcinomaEBV-Related Sarcoma
- Interventions
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Viracta Therapeutics, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05166577
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
- Conditions
- EBV Related Non-Hodgkin's LymphomaEBV-Positive DLBCL, NOSEBV Related PTCL, NOSEpstein-Barr Virus Associated Lymphoproliferative DisorderEBV-Related PTLDEBV Associated Lymphoma
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Viracta Therapeutics, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05011058
- Locations
- 🇺🇸
The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸David Geffen School of Medicine - UCLA, Los Angeles, California, United States
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
- Conditions
- Epstein-Barr Virus-Associated LymphomaLymphoproliferative Disorders
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Viracta Therapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT03397706
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸UC Irvine Chao Family Comprehensive Cancer Center, Orange, California, United States
ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past
- Conditions
- HIV Infections
- Locations
- 🇺🇸
ViRx Inc, San Francisco, California, United States